CSL has announced the US Food
and Drug Administration approval
of its AFSTYLA (Antihaemophilic
Factor [Recombinant] Single
Chain), which is a novel long-lasting
recombinant factor VIII single-chain
therapy for adults and children
with haemophilia A made by its CSL
Behring offshoot.The above snippet is the first part of an article sent to subscribers in Pharmacy Daily's issue from 27 May 16 To see the full story, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 27 May 16
THE NSW Health Care Complaints Commission (HCCC) has prosecuted a complaint against pharmacist Nicholas Fearon before the NSW Civil and Administrative Tribunal, which found him guilty of unsatisfactory professional conduct and professional misconduct, and having been convicted of a criminal offence in NSW, was not a suitable person to hold registration as a pharmacist.
SIGMA Healthcare says 2017/18 was a “challenging year” during which it continued to execute its long term strategy despite declining sales due to softening consumer sentiment and reduced demand for low-margin Hepatitis C drugs.